De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

As Bio­gen takes a pre­clin­i­cal De­nali com­pound tar­get­ing amy­loid be­ta for­ward in Alzheimer’s, De­nali is shelv­ing an­oth­er Alzheimer’s can­di­date that is part­nered with Take­da and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER